One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Iron Deficiency Anemia Therapy Market

[ 英語タイトル ] Iron Deficiency Anemia Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0082600
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Allergen
- Akebia Therapeutics
- AMAG Pharmaceuticals
- Keryx Biopharmaceuticals Inc.
- Luitpold Pharmaceuticals Inc.
- Pharmacosmos AS
- Pieris
- Sanofi Aventis

[Report Description]

The iron deficiency anemia therapy market is expected to register a CAGR of nearly 7.2% during the forecast period, 2019-2024. Iron deficiency anemia is a common condition affecting, especially, children and young women across the world. Iron deficiency is a major problem in developed countries, such as the United States, Canada, the United Kingdom, and across Europe.

Moreover, in developing countries, iron deficiency anemia is frequently exacerbated by malaria and other worm infections. Accordig to the World Health Organization, 2017, Africa bears the highest burden of malaria with about around 90% cases. The current market is growing, due to the rising incidences of iron deficiency anemia. The increasing risk of hemodilution in pregnant women acts as a major driver for this market. The need to reduce the burden of iron-deficiency anemia has led to an increase in the demand for its treatment, which subsequently drives the global market.

Key Market Trends

Parenteral Iron Therapy Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

- Parenteral iron therapy is generally offered to patients who are either unable to absorb oral iron or are still diagnosed with increasing anemia, even after taking adequate doses of oral iron supplements. Many intravenous iron supplementation products are being approved by regulatory authorities, which is likely to drive the market in the future.
- Furthermore, according to the study published in Cochrane Library, 2019, parenteral iron therapy has shown to be very effective in case of patients with inflammatory bowel disease, postpartum hemorrhage and chronic heart failure. Also, advantages over the oral therapy is expected to boost the demand for parenteral iron therapy. Some patients are intolerant towards oral iron therapy, hence prefers parenteral iron therapy. Therefore, the aforementioned factors are expected to influence positively on the market in this segment.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall iron deficiency anemia therapy market, with the United States being the major contributor to the market. According to the study of Mechanisms of Ageing and Development, 2018, iron deficiency anemia is highly prevalent in pregnant women and children. In the United States, the prevalence rate of iron deficiency anemia was found to be around 10% in women of child bearing age while one third of the children (12 months to 36 months) are likely to suffer from it. Moreover, the increasing product approvals related to iron deficiency anemia therapy is expected to be the major contributor in the market. For instance, recently, Pharmacosmos AS, recieved an US FDA approval for it's product "Monoferric" for the treatment of iron deficiency anemia.Hence, the high prevalence rate of anemia is expected to boost the growth of the market in North America.

Competitive Landscape

Companies are taking initiatives to develop novel therapies in the market. For instance, in 2018, AMAG Pharmaceuticals recieved an US FDA (Food & Drug Administration) approval for Feraheme for the treatment of iron deficiency anemia in patients with intolerance to oral iron therapy and/or have no significant improvement through oral iron therapy. The presence of a significant number of players in the market studied has an impact on the prices of products by firms, such as Allergan, Pharmacosmos AS, AMAG Pharmaceuticals, Sanofi Aventis, Pieris, Lutipold, Keryx Biopharmaceuticals Inc. and Akebia Therapeutics.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Anemia
4.2.2 Increasing Research and Development Activities Related to the Product
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Adverse Effects
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5.1 Therapy Type
5.1.1 Oral Iron Therapy
5.1.2 Parenteral Iron Therapy
5.1.3 Red Blood Cell Transfusion
5.1.4 Others
5.2 End User
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Home Healthcare
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Allergen
6.1.2 Akebia Therapeutics
6.1.3 AMAG Pharmaceuticals
6.1.4 Keryx Biopharmaceuticals Inc.
6.1.5 Luitpold Pharmaceuticals Inc.
6.1.6 Pharmacosmos AS
6.1.7 Pieris
6.1.8 Sanofi Aventis




Recommended reports